HRP20210040T1 - (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina - Google Patents

(2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina Download PDF

Info

Publication number
HRP20210040T1
HRP20210040T1 HRP20210040TT HRP20210040T HRP20210040T1 HR P20210040 T1 HRP20210040 T1 HR P20210040T1 HR P20210040T T HRP20210040T T HR P20210040TT HR P20210040 T HRP20210040 T HR P20210040T HR P20210040 T1 HRP20210040 T1 HR P20210040T1
Authority
HR
Croatia
Prior art keywords
crystalline form
compound
compound according
methyloxazole
fluorobiphenyl
Prior art date
Application number
HRP20210040TT
Other languages
English (en)
Croatian (hr)
Inventor
Melissa Fleury
Adam D. Hughes
Anne-Marie Beausoleil
Erik FENSTER
Venkat R. Thalladi
Miroslav Rapta
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of HRP20210040T1 publication Critical patent/HRP20210040T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HRP20210040TT 2015-02-19 2016-02-12 (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina HRP20210040T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118067P 2015-02-19 2015-02-19
PCT/US2016/017699 WO2016133803A1 (en) 2015-02-19 2016-02-12 (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
EP16708268.4A EP3259255B1 (en) 2015-02-19 2016-02-12 (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

Publications (1)

Publication Number Publication Date
HRP20210040T1 true HRP20210040T1 (hr) 2021-04-02

Family

ID=55456914

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210040TT HRP20210040T1 (hr) 2015-02-19 2016-02-12 (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina

Country Status (29)

Country Link
US (6) US9533962B2 (enExample)
EP (1) EP3259255B1 (enExample)
JP (1) JP6714009B2 (enExample)
KR (1) KR102573351B1 (enExample)
CN (1) CN107250119B (enExample)
AU (1) AU2016220348B2 (enExample)
BR (1) BR112017017783A2 (enExample)
CA (1) CA2975269C (enExample)
CO (1) CO2017008426A2 (enExample)
CY (1) CY1123728T1 (enExample)
DK (1) DK3259255T3 (enExample)
ES (1) ES2857101T3 (enExample)
HR (1) HRP20210040T1 (enExample)
HU (1) HUE052732T2 (enExample)
IL (1) IL253759B (enExample)
LT (1) LT3259255T (enExample)
MX (1) MX370065B (enExample)
MY (1) MY191183A (enExample)
PH (1) PH12017501444A1 (enExample)
PL (1) PL3259255T3 (enExample)
PT (1) PT3259255T (enExample)
RS (1) RS61325B1 (enExample)
RU (1) RU2715241C2 (enExample)
SG (1) SG11201706662YA (enExample)
SI (1) SI3259255T1 (enExample)
SM (1) SMT202100028T1 (enExample)
TW (1) TWI707846B (enExample)
WO (1) WO2016133803A1 (enExample)
ZA (1) ZA201705487B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2864292T (pt) * 2012-06-08 2017-07-10 Theravance Biopharma R&D Ip Llc Inibidores de neprisilina
AU2016220348B2 (en) 2015-02-19 2019-10-17 Theravance Biopharma R&D Ip, Llc (2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
KR102238177B1 (ko) 2017-09-15 2021-04-07 주식회사 엘지화학 전지셀 및 전극 리드 제조방법
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
JP7579322B2 (ja) 2019-07-03 2024-11-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｓ）－３－ヒドロキシ－１－（１ｈ－インドール－５－イル）－２－オキソ－ピロリジン－３－カルボン酸３，５－ジフルオロ－ベンジルアミドを製造するためのプロセス

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189604A (en) 1975-07-22 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Bestatin
US4206232A (en) 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4906615A (en) 1980-12-18 1990-03-06 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US4722810A (en) 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
US4939261A (en) 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
EP0225292A3 (en) 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
US4929641B1 (en) 1988-05-11 1994-08-30 Schering Corp Mercapto-acylamino acid antihypertensives
KR880007441A (ko) 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
FR2623498B1 (fr) 1987-11-24 1990-04-06 Bioprojet Soc Civ Nouveaux composes enantiomeres derives d'amino-acides, leur procede de preparation et leurs applications therapeutiques
GB8820844D0 (en) 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
US5599951A (en) 1989-09-15 1997-02-04 Societe Civile Bioprojet Amino acid derivatives, the process for their preparation and their applications to therapy
US5294632A (en) 1991-05-01 1994-03-15 Ciba-Geigy Corporation Phosphono/biaryl substituted dipetide derivatives
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
AU5687396A (en) 1995-04-21 1996-11-07 Novarits Ag N-aroylamino acid amides as endothelin inhibitors
US6660756B2 (en) 2001-03-28 2003-12-09 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
MY151993A (en) 2007-01-12 2014-07-31 Novartis Ag Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
PE20091364A1 (es) 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
ES2582395T3 (es) * 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
MX2011012628A (es) * 2009-05-28 2011-12-14 Novartis Ag Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
US8372984B2 (en) * 2009-07-22 2013-02-12 Theravance, Inc. Dual-acting oxazole antihypertensive agents
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
AU2011207020B2 (en) 2010-01-22 2014-04-17 Novartis Ag Intermediates of neutral endopeptidase inhibitors and preparation method thereof
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
AU2011343903B2 (en) 2010-12-15 2016-06-30 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
DK2651896T3 (en) 2010-12-15 2015-10-05 Theravance Biopharma R & D Ip Llc Neprilysininhibitorer
JP5959065B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP5959066B2 (ja) 2011-02-17 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
CN103748070B (zh) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
US8513244B2 (en) 2011-05-31 2013-08-20 Theravance, Inc. Neprilysin inhibitors
ES2699773T3 (es) 2011-05-31 2019-02-12 Theravance Biopharma R&D Ip Llc Inhibidores de neprilisina
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
WO2013181332A1 (en) 2012-05-31 2013-12-05 Theravance, Inc. Nitric oxide donor neprilysin inhibitors
PT2864292T (pt) 2012-06-08 2017-07-10 Theravance Biopharma R&D Ip Llc Inibidores de neprisilina
JP6162229B2 (ja) 2012-06-08 2017-07-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
SG11201500845UA (en) 2012-08-08 2015-03-30 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
HUE034210T2 (hu) 2013-03-05 2018-02-28 Theravance Biopharma R&D Ip Llc Neprilizininhibitorok
US9585882B2 (en) * 2014-01-30 2017-03-07 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
MY187899A (en) 2015-02-11 2021-10-27 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
AU2016220348B2 (en) 2015-02-19 2019-10-17 Theravance Biopharma R&D Ip, Llc (2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

Also Published As

Publication number Publication date
CO2017008426A2 (es) 2017-11-10
EP3259255B1 (en) 2020-10-21
MY191183A (en) 2022-06-04
HK1245772A1 (zh) 2018-08-31
BR112017017783A2 (pt) 2018-07-17
SG11201706662YA (en) 2017-09-28
DK3259255T3 (da) 2021-01-18
US20190269659A1 (en) 2019-09-05
US20160244416A1 (en) 2016-08-25
TWI707846B (zh) 2020-10-21
US20180228774A1 (en) 2018-08-16
MX370065B (es) 2019-11-29
US11642332B2 (en) 2023-05-09
RS61325B1 (sr) 2021-02-26
IL253759A0 (en) 2017-09-28
LT3259255T (lt) 2021-04-26
US10548879B2 (en) 2020-02-04
SI3259255T1 (sl) 2021-04-30
MX2017010666A (es) 2017-11-16
IL253759B (en) 2020-10-29
ZA201705487B (en) 2018-05-30
HUE052732T2 (hu) 2021-05-28
JP6714009B2 (ja) 2020-06-24
WO2016133803A1 (en) 2016-08-25
US20170196841A1 (en) 2017-07-13
US9872855B2 (en) 2018-01-23
EP3259255A1 (en) 2017-12-27
CN107250119A (zh) 2017-10-13
PT3259255T (pt) 2021-01-26
PL3259255T3 (pl) 2021-07-26
AU2016220348A1 (en) 2017-08-17
CY1123728T1 (el) 2022-05-27
US20210401808A1 (en) 2021-12-30
RU2017132430A3 (enExample) 2019-08-12
KR20170118855A (ko) 2017-10-25
ES2857101T3 (es) 2021-09-28
AU2016220348B2 (en) 2019-10-17
TW201638074A (zh) 2016-11-01
CN107250119B (zh) 2020-09-22
US10172834B2 (en) 2019-01-08
KR102573351B1 (ko) 2023-09-01
RU2017132430A (ru) 2019-03-19
CA2975269C (en) 2023-09-19
US20200281900A1 (en) 2020-09-10
SMT202100028T1 (it) 2021-03-15
RU2715241C2 (ru) 2020-02-26
US9533962B2 (en) 2017-01-03
PH12017501444A1 (en) 2018-01-15
CA2975269A1 (en) 2016-08-25
JP2018507207A (ja) 2018-03-15
US11033533B2 (en) 2021-06-15
NZ734623A (en) 2021-01-29

Similar Documents

Publication Publication Date Title
HRP20210040T1 (hr) (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina
TWI475997B (zh) ３－（１－｛３－〔５－（１－甲基－六氫吡啶－４－基甲氧基）－嘧啶－２－基〕－苄基｝－６－酮基－１，６－二氫－噠嗪－３－基）苯甲腈氫氯酸鹽之新穎多晶形及其製法
ES2277149T3 (es) Derivados de piridina como moduladores de los receptores cb2.
RU2016136823A (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
HRP20210681T1 (hr) Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida
TW200813016A (en) Novel heterocyclic substituted pyridine compounds with CXCR3 antagonist activity
CN109923114A (zh) 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
JP2016014037A (ja) 縮合複素環式化合物およびそれらの使用
RU2017131522A (ru) (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота
HRP20171201T1 (hr) Postupak kristalizacije i biodostupnost
JP2016537366A5 (enExample)
JP2016523974A (ja) Ｉｄｏ阻害剤
CN105837560A (zh) 调控jak激酶的喹唑啉衍生物和其使用方法
JP2015529234A5 (enExample)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
HRP20180411T1 (hr) Predlijekovi inhibitora aminokinazolinske kinaze
HRP20241633T1 (hr) 2,4-disupstituirani derivat pirimidina, postupak njegove pripreme i njegova uporaba
HRP20171763T1 (hr) Derivati piridin-4-ila
JP6978002B2 (ja) チエノ−ピリミジン誘導体およびその使用
RU2016141650A (ru) Амидные соединения
JP2018507207A5 (enExample)
RS20080246A (sr) 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
ES2691270T3 (es) Derivados del tetrazol y su uso como moduladores de los canales de potasio
CA2813063A1 (en) Antagonist for mutated androgen receptor
RS65334B1 (sr) Kristalni oblici inhibitora fosfatidilinozitol 3-kinaze (pi3k)